Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) | RFA CA 19 028

Opportunity Information: Apply for RFA CA 19 028

This grant opportunity, titled "Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)," is a National Institutes of Health (NIH), National Cancer Institute (NCI) funding announcement (RFA-CA-19-028) that supports revision applications to existing awards rather than brand-new, stand-alone projects. It is specifically aimed at investigators who already hold an active NCI U2C Resource-Related Multi-Component Project or Center award and want to submit a competitive revision (now typically called a "revision application") to expand the original scope of their parent project or speed up progress on the parent study. The central idea is to bring in a new technical approach or instrument that was developed with support from the NCI Innovative Molecular Analysis Technologies (IMAT) program, and then use that tool to enhance, extend, or accelerate the cancer research already underway in the U2C project.

A key purpose of the program is to encourage independent validation of emerging IMAT-supported technologies in real research settings, so that promising new methods can be tested, proven, and made more broadly usable by the cancer research community. In practice, this means the revision work is expected to do more than simply adopt a new gadget or method; it should generate credible evidence that the technology works as intended, fits the needs of researchers, and can meaningfully advance the scientific goals of the parent award. The FOA also emphasizes interdisciplinary collaboration, reflecting the IMAT program's broader mission to bring together teams across fields (for example, engineering, computational science, molecular analysis, and oncology) to develop and apply novel tools that can open up new scientific possibilities and speed discovery.

The award mechanism is a cooperative agreement (U2C), which generally indicates a more substantial level of scientific or programmatic involvement by the funding agency than a standard grant. The activity area is listed under education and health, and the relevant CFDA number is 93.394. The announcement indicates clinical trials are optional, meaning applicants may propose clinical trial-related activities if appropriate, but a clinical trial is not required as the defining feature of the revision.

Eligibility is broad in terms of organizational types, but it is still constrained by the requirement that the applicant must be revising an existing, currently funded NCI U2C Resource-Related Multi-Component Project or Center award. Eligible applicant organizations include many public entities (such as state, county, city or township governments, special district governments, and eligible federal agencies), education organizations (including public/state-controlled and private institutions of higher education, and independent school districts), and a wide range of nonprofit and for-profit entities (including 501(c)(3) and non-501(c)(3) nonprofits, as well as for-profit organizations other than small businesses and small businesses). The FOA also calls out additional categories of eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and certain tribal governments or tribal organizations.

Foreign eligibility is limited in a specific way. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply as the applicant organization. However, foreign components are allowed as defined by the NIH Grants Policy Statement, meaning a U.S.-based applicant may include a foreign component when it is scientifically justified and consistent with NIH policy, even though a foreign institution cannot be the primary applicant.

In terms of funding scale and timing, the opportunity lists an award ceiling of $150,000. The original closing date provided is September 27, 2019, and the opportunity was created on January 7, 2019. Although the posting includes "ExpectedAwards:" without a specific number filled in, the overall structure suggests a targeted revision supplement-style competition intended to catalyze adoption and validation of IMAT-developed technologies within active U2C center-style projects.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
• This funding opportunity was created on 2019-01-07.
• Applicants must submit their applications by 2019-09-27. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $150,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 19 028

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: